New study analyzes cost effectiveness of smoked cannabis to treat chronic neuropathic pain
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, January 29, 2019–Smoked cannabis as an adjunctive second-line therapy to treat chronic peripheral neuropathy can be both effective and cost-effective. The results of a new study simulating its use in one million patients are published in Cannabis and Cannabinoid Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Cannabis and Cannabinoid Research website.
In the article entitled “A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain,” David Grelotti, MD, University of California San Diego (La Jolla) and coauthors from UCSD, University of California Center for Medicinal Cannabis Research (San Diego), and Columbia University (New York, NY) created a computer simulation to compare the cost of usual first-, second-, and third-line care with those supplemented with smoked cannabis. They modeled efficacy and adverse events based on clinical trial and other existing study data, and derived cannabis cost from retail market pricing.
“With the opioid crisis continuing unabated, it is essential to understand whether cannabis might offer a safe, effective, and economically sound approach to pain management. This article offers new data that will help evaluate this possibility,” says Editor-in-Chief Daniele Piomelli, PhD, PharmD, University of California-Irvine, School of Medicine.
Research reported in this publication was supported by the National Institutes of Health under Award Number 1TL1TR001443. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Cannabis and Cannabinoid Research is the only peer-reviewed journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. Published quarterly in print and online and led by Editor-in-Chief Daniele Piomelli, PhD, PharmD, the Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies. Complete tables of content and a sample issue is available on the Cannabis and Cannabinoid Research website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Palliative Medicine, The Journal of Alternative and Complementary Medicine, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Related Journal Article